A series of first-line chemotherapeutic drugs, including doxorubicin, paclitaxel and mitoxantrone are substrates of ABC transporters, meaning that these anti-cancer drugs will be pumped out from the cancer cells and finally lead to the failure of clinical carcinoma treatment (1–4, 34). The gene discussed is ABCG2; the disease is carcinoma.